Atai subsidiary wraps up enrollment for clinical study of r-ketamine

Mental health–focused biopharma Atai Life Sciences (Nasdaq:ATAI) recently completed enrollment in a Phase 2a study of PCN-101 (r-ketamine) for treatment-resistant depression.

The company’s Perception Neuroscience division expects top-line results from the trial before the end of 2022.

R-ketamine is an enantiomer of ketamine. Conversely, racemic ketamine is composed of equal amounts of s-ketamine and r-ketamine. We included r-ketamine in our list of emerging antidepressants.

Johnson & Johnson (NYSE:JNJ) has achieved intellectual property protection for S-ketamine and, in 2019, won FDA approval for s-ketamine for treatment-resistant depression.

The company notes that PCN-101 could be a potentially rapid-acting therapeutic for treatment-resistant depression (TRD) that can be administered at home.

[R-ketamine image courtesy of PubChem]

“We anticipate this therapy to be administered i…
Read more
  • 0